Location

Please check the individual session for location or broadcast availability.  

Frequency

Weekly

Series Director

Murali Chintagumpala, MBBS

Target Audience

This activity is intended for neurosurgeons, neuropathologists, neuroradiologists, pediatric oncologists, and the trainees in these fields who contribute to the management of pediatric neuro-oncology patients.

Needs Statement

To address practice gaps in the methods of diagnosis, molecular diagnosis of subtypes, new drugs and technologies, end points in the conduct of clinical trials with targeted agents, and long-term treatment-related toxicities for pediatric patients with brain tumors, clinicians require targeted education on several fronts that this tumor board series will aim to address through case presentations and interactive discussion. First, there is a need for enhanced understanding of molecular and imaging diagnostics, gene fusions, and advanced imaging findings to guide diagnosis and treatment planning. Second, providers must be equipped to evaluate and select among emerging therapeutic options with a clear understanding of their efficacy, safety profiles, and appropriate clinical contexts. Third, education will focus on the application of pediatric-specific clinical trial response criteria to ensure accurate assessment of treatment outcomes and alignment with current research standards. Lastly, clinicians must be trained to recognize and manage treatment-related toxicities.

Educational Methods

Educational methods will include case presentations.

Objectives

At the conclusion of the sessions, the participants should be able to:

• Apply current molecular tests and imaging criteria to accurately diagnose and classify pediatric brain tumors and inform treatment planning.
• Correlate imaging findings with therapeutic response to specific treatments to anticipate long-term outcomes.
• Develop multidisciplinary treatment strategies that integrate emerging targeted therapies while accounting for patient-specific risk factors such as age, molecular subtype, and treatment-related toxicities.

Evaluation

Participants may be asked to complete a session evaluation.

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Series Coordinator